TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Strategic Timing of Antiretroviral Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
INCLUSION CRITERIA:~* Signed informed consent~* HIV infection documented by a plasma HIV RNA viral load, rapid HIV test or any licensed\* ELISA test; and confirmed by another test using a different method including but not limited to a rapid HIV test, Western Blot, HIV culture, HIV antigen, or HIV pro-viral DNA at any time prior to study entry.~* Age greater than or equal to 18 years~* Karnofsky performance score greater than or equal to 80 (an indication that the participant can perform normal activities)~* Perceived life expectancy of at least 6 months~* For women of child-bearing potential, willingness to use contraceptives as described in the product information of the ART drugs they are prescribed~* Two CD4+ cell counts greater than 500 cells/mm(3) at least 2 weeks apart within 60 days before randomization~  * The term licensed refers to an FDA-approved kit or, for sites located in countries other than the United States, a kit that has been certified or licensed by an oversight body within that country. Confirmation of the initial test result must use a test method that is different than the one used for the initial assessment.~EXCLUSION CRITERIA:~* Any previous use of ART or interleukin-2 (IL-2)~* Diagnosis of any clinical AIDS event before randomization (including esophageal candidiasis and chronic Herpes simplex infection)~* Presence of HIV progression such as oral thrush, unexplained weight loss, or unexplained fever~* Cardiovascular event (myocardial infarction, angioplasty, coronary-artery bypass grafting, stroke) within 6 months before randomization~* Non-AIDS-defining cancer, excluding basal and squamous cell skin cancer, within 6 months before randomization~* Dialysis within 6 months before randomization~* Diagnosis of decompensated liver disease before randomization~* Current imprisonment, or compulsory detention (involuntary incarceration) for treatment of a psychiatric or physical illness~* Current pregnancy or breastfeeding (a negative serum or urine pregnancy test is required within 14 days before randomization for women of child-bearing potential)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Early ART (Type: EXPERIMENTAL): Initiate ART immediately following randomization
- Deferred ART (Type: ACTIVE_COMPARATOR): Defer ART until the CD4+ count declines to \<350 cells/cu mm or AIDS develops

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of GX-I7 in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject is willing and able to give informed consent after listening character of the clinical trial~2. Must be 19-45 years of age, inclusive~3. Weight 50-100kg, BMI 18-30kg/m2~4. Subject who is adequately able to attend the study based on medical history and physical exam, no clinically significant abnormality from vital sign and clinical laboratory values~5. No clinical abnormality from ECG test~6. Non-smoker (no smoking or no use of any product containing nicotine least for one month and negative from urine test)~Exclusion Criteria:~1. Suspected or confirmed malignancy, or has malignancy history~2. Any clinically significant acute or chronic medical condition requiring care of a physician, in liver, biliary tract, renal, nervous system (CNS or peripheral). respiratory system, endocrine (diabetes, hyperlipidemia etc), cardiovascular (congestive heart failure, coronary artery disease, myocardial infarction etc), hematology, malignancy, urinary disease, mental disorder, musculoskeletal disorder, immune system (rheumatoid arthritis, lupus etc), otorhinolaryngologic diseases~3. Positive to HBsAg, hepatitis C virus (HCV) Ab and HIV Ab~4. Are considering or scheduled to undergo any surgical or dental procedure during the study~5. Administered other Investigational Product (IP) by attending other clinical study or biological equivalent study within recent 3 months~6. Any Serious adverse drug reaction (SAR) against vaccines or antibiotics, any medical history with serious allergic diseases~7. Positive from urine drug screen or respiratory alcohol screen at medical screening or check-in~8. History of alcohol, drug, or substance abuse in the past 12 months~9. Consumption of alcohol within 48 hours prior to hospitalization~10. Medications with antacid, analgesic, herbal treatment, vitamin, mineral (except maximum 4 grams of acetaminophen) hormone, steroids, insulin, hypoglycemic drug or other hormone substitute within 14 days before administration~11. Planning pregnancy or donation of sperm/disagreeing proper contraception during the study and 3 months following IP administration~12. Do not have veins suitable for cannulation or multiple venipunctures~13. Any other factor that the Investigator thinks will increase subject risk with participation

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): GX-I7 SC 20㎍/㎏ (8 subjects) / Placebo (2 subjects)
- Cohort 2 (Type: EXPERIMENTAL): GX-I7 SC 60㎍/㎏ (8 subjects) / Placebo (2 subjects)
- Cohort 3 (Type: EXPERIMENTAL): GX-I7 IM 60㎍/㎏ (8 subjects) / Placebo (2 subjects)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Metastatic Rhabdomyosarcoma or Sarcoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed metastatic stage IV/clinical group IV rhabdomyosarcoma, undifferentiated sarcoma, or ectomesenchymoma~  * No metastatic embryonal tumors in patients under 10 years of age, regardless of primary site~ * Metastatic tumors of parameningeal sites eligible~* Bidimensionally measurable disease~* No positive cerebrospinal fluid cytology or multiple intracranial metastases~* Patients presenting with the following are only eligible for continuation therapy and may not receive irinotecan/vincristine upfront window therapy:~  * Evidence of base of skull erosion or skull metastatic disease that displaces or indents the dura, compresses the brain parenchyma, or causes evidence of cranial nerve palsy~ * Tumor that touches or displaces the spinal cord~ * Evidence of intracranial primary tumor extension~ * Tumors that could cause potentially life-threatening complications (e.g., renal, airway) with progression due to location and/or growth rate~ * Requires emergency radiotherapy~ * Lab values are consistent with disseminated intravascular coagulation~PATIENT CHARACTERISTICS:~Age:~* Under 50 (alveolar rhabdomyosarcoma, undifferentiated sarcoma, and ectomesenchymoma patients)~* 10 to 49 (embryonal histology patients)~Performance status:~* Not specified~Life expectancy:~* Not specified~Hematopoietic:~* See Disease Characteristics~* Absolute neutrophil count greater than 1,000/mm\^3\*~* Platelet count greater than 150,000/mm\^3\* NOTE: \*Unless there is tumor involvement of bone marrow~Hepatic:~* Bilirubin less than 1.5 mg/dL~* PT, PTT, and fibrinogen less than 1.5 times upper limit of normal~Renal:~* Creatinine less than 1.2 mg/dL~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* No prior chemotherapy~Endocrine therapy:~* Prior steroids allowed~Radiotherapy:~* See Disease Characteristics~* No prior radiotherapy~Surgery:~* No more than 42 days since prior initial surgical procedure, including biopsy for diagnosis

- Gender: ALL
- Minimum Age: None
- Maximum Age: 49 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Respiratory and Autonomic Plasticity Following Intermittent Hypoxia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Characteristics of OSA subject population:~* Body mass index \< 30 kg/m2.~* 20 to 40 years old.~* Newly diagnosed never-treated mild to moderate sleep apnea (i.e. 50 \> apnea/hypopnea index \>10 events per hour - average nocturnal oxygen saturation \> 90%).~* Not pregnant.~* Free of any other known medical conditions.~* Not taking any medication.~* Non-smokers with normal lung function.~* Minimal alcohol consumption (i.e. no more than the equivalent of a glass of wine/day).~Characteristics of control group population:~* Body mass index \< 30 kg/m2.~* 20 to 40 years old.~* Apnea/hypopnea index \< 5 events per hour.~* Not pregnant.~* Free of any known medical conditions.~* Not taking any medication.~* Non-smokers with normal lung function.~* Minimal alcohol consumption (i.e. no more than the equivalent of a glass of wine/day).~Exclusion Criteria:~* Anything not in inclusion criteria.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Arm 1 (Type: NO_INTERVENTION): We plan to study 10 males and 10 females with moderate obstructive sleep apnea (OSA), and 10 healthy males and 10 healthy females. The males and the females will be matched based on age, race, sex and body mass index. The OSA and control participants will be exposed to intermittent hypoxia and sham intermittent hypoxia during wakefulness and sleep.
- ANTIOXIDANT COCKTAIL (Type: EXPERIMENTAL): We plan to study 10 male participants with moderate obstructive sleep apnea (OSA) and 10 male control participants matched for age, race and body mass index. The OSA and control participants will be exposed to intermittent hypoxia during wakefulness and sleep following administration of an antioxidant or a placebo cocktail that will be presented in a randomized fashion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Botanical Oil Supplementation in Diabetic and Metabolic Syndrome Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* adults, aged 21 years or more with either diabetes or metabolic syndrome. metabolic syndrome defined by NCEP/ATPIII criteria; must have 3 out of 5 of the following risk factors: 1.central obesity, men-greater than or equal to 40 inches, women-greater than or equal to 35 inches; 2.fasting blood TG greater than or equal to 150mg/dl or be taking TG lowering medications; 3. blood HDL cholesterol, men less than 40 mg/dl, women less than 50 mg/dl; 4. blood pressure greater than or equal to 130/85 or on HTN medication 5. fasting glucose greater than or equal to 100 mg/dl.~* participants on statins or glucose lowering drugs if dosages are stable for 3 months~Exclusion criteria~* children/young adults less than 21 years of age~* currently using anti-inflammatory drugs including NSAIDS, oral/IV steroids or injection antiinflammatory drugs(for RA), aspirin greater than 100mg/day~* taking leukotriene receptor antagonists ( montelukast), tylenol or nasal/inhaled steroids OK.~* currently using niacin, fibrates or fish oil~* blood pressure greater than 170/100~* HB1Ac greater than 10%~* TG greater than 500 mg/dl~* myocardial infarction/vascular surgery/stroke within the past year~* any stage II,III,IV heart failure~* prior cholecystectomy~* end stage renal disease~* BMI less than 23 or greater than 45~* pregnancy~* alcohol use greater than 14 drinks per week~* current self reported tobacco or illicit drug use~* intolerance or allergy to fish oil~* participants taking insulin on QD or BID doses, stable for 3 months

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- borage and echium oil combination (Type: EXPERIMENTAL): borage/echium oil combination containing 0.85g/day SDA and 1.7 g/day GLA
- fish oil (Type: ACTIVE_COMPARATOR): Croda 18:12 fish oil
- corn oil (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Endoscopic Therapy of Early Cancer in Barretts Esophagus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Non-recurrent adenocarcinoma in Barrett's Esophagus confirmed by two experienced gastrointestinal pathologists~* No evidence of submucosal invasion~* No evidence of metastatic disease in either regional or distal lymph nodes, or other organs~* Pre-entry CT scans of the upper abdomen and chest and Endoscopic Ultrasound (EUS) of the tumor and regional lymph nodes are required. Fusion PET scans are suggested for any indeterminate lesions~* Zubrod Performance Status 0-1~* Participants must be have oral intake of greater than 1700 calories a day~* Patient must not have had a second malignancy, other than curable non-melanoma skin cancer or cervical cancer in situ, unless disease free for greater than or equal to 3 years and deemed cured by their hematologist and/or oncologist~* Staging procedures should be performed prior to study entry~* All patients or legally authorized representative must sign a study-specific informed consent prior to randomization.~Exclusion criteria:~* Prior major esophageal surgery~* Patients who are unable to tolerate endoscopic procedures~* Due to the possible toxic effects of photodynamic therapy and endoscopic sedation to embryos, pregnant or lactating women or men unable or unwilling to practice contraception are excluded~* Patients with an uncontrolled diabetes, heart disease, or hypertension~* Patient and/or legally authorized representative who are unable to comprehend the study requirements or who are not likely to comply with the study parameters.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Endoscopic Mucosal Resection (Type: OTHER): Patients will undergo endoscopic mucosal resection at time of endoscopy if indicated.
- Photodynamic Therapy (Type: OTHER): Patients will have endoscopic mucosal resection with photodynamic therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Extension Study to Evaluate MBA-P01 in Subjects With Moderate to Severe Glabellar Lines

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who completed the phase III trial (MT14-KR20GBL309)~* Patients who were capable of understanding and complying with the protocol and have signed the informed consent form voluntarily~Exclusion Criteria:~* Patients who have received other procedures which may affect glabellar lines within 6 months (except of MBA-P01 or BOTOX® treated in phase III trial, MT14-KR20GBL309)~* Female patients who are pregnant or lactating. Female patients of childbearing age who have a plan to get pregnant during the study period.~* Patient who do not use available contraceptive methods (Women of childbearing age should have negative urine pregnancy test results at baseline visit (0 week) prior to the first injection.)~* Patients who are participating in other clinical trials or have participated in other clinical trials 30 days before screening~* Patients who are not eligible for this study based on the judgment of an investigator

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- MBA-P01 (Type: EXPERIMENTAL): MBA-P01 will be injected into GL:

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Participants with hypercholesterolemia and established coronary heart disease (CHD) or CHD risk equivalents who were not adequately controlled with a maximally tolerated daily dose of statin with or without other LMT, both at stable dose for at least 4 weeks to 6 weeks prior to screening (Week -2)~Exclusion criteria:~* Age \<18 or legal age of adulthood, whichever was greater~* Participants without established CHD or CHD risk equivalent~* LDL-C \<70 mg/dL (\<1.81 mmol/L) and participants with a history of documented cardiovascular disease~* LDL-C \<100 mg/dL (\<2.59 mmol/L) and participants without a history of documented cardiovascular disease~* Not on a stable dose of LMT (including statin) for at least 4 weeks and/or fenofibrate for at least 6 weeks, as applicable, prior to the screening visit (Week -2) and from screening to randomization~* Fasting serum triglycerides \> 400 mg/dL (\>4.52 mmol/L)~The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo Q2W (Type: PLACEBO_COMPARATOR): Placebo (for alirocumab) every 2 weeks (Q2W) added to stable Lipid-Modifying Therapy (LMT) for 52 weeks.
- Alirocumab (Type: EXPERIMENTAL): Alirocumab 75 mg Q2W added to stable LMT for 52 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) at Week 8.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effectiveness and Efficacy of the Combination of the Integrated Psychological Therapy and Metacognitive Training.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of schizophrenia~* No relapse and hospitalization~* Ambulant psychiatric treatment~Exclusion Criteria:~* Other psychotic disorders~* Relapse and hospitalization~* Substance abuse

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Therapy Group A (Type: EXPERIMENTAL): Therapy Group A Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented.~5 individuals with schizophrenia
- Therapy Group B (Type: EXPERIMENTAL): Therapy Group B Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented.~2 individuals with schizophrenia
- Therapy Group C (Type: EXPERIMENTAL): Therapy Group C Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented.~8
- Therapy Group D (Type: EXPERIMENTAL): Therapy Group D Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented.~8
- Therapy Group E (Type: EXPERIMENTAL): Therapy Group E Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented.~3
- Therapy Group F (Type: EXPERIMENTAL): Therapy Group F Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented.~3
- Therapy Group G (Type: EXPERIMENTAL): Therapy Group G Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented 3
- Therapy Group H (Type: EXPERIMENTAL): Therapy Group H Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented.~3

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete